Quadrature Capital Ltd Cuts Position in McKesson Corporation $MCK

Quadrature Capital Ltd decreased its position in McKesson Corporation (NYSE:MCK) by 36.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,489 shares of the company’s stock after selling 19,010 shares during the quarter. Quadrature Capital Ltd’s holdings in McKesson were worth $25,109,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in MCK. Norges Bank acquired a new position in McKesson during the 2nd quarter worth approximately $1,346,661,000. Alliancebernstein L.P. raised its holdings in shares of McKesson by 150.4% in the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after purchasing an additional 1,362,386 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after purchasing an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of McKesson by 45.6% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after purchasing an additional 261,296 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of McKesson by 2.0% during the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after purchasing an additional 232,286 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, Director Maria Martinez sold 349 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the transaction, the director owned 301 shares in the company, valued at $282,900.87. This trade represents a 53.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,868 shares of company stock worth $3,743,820. Insiders own 0.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on MCK. Wells Fargo & Company increased their target price on McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a report on Thursday, February 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research report on Thursday, January 29th. Mizuho increased their price objective on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Evercore restated an “outperform” rating on shares of McKesson in a research note on Thursday, March 5th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $960.93.

McKesson Price Performance

Shares of NYSE:MCK opened at $943.88 on Friday. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The firm has a market capitalization of $115.62 billion, a P/E ratio of 27.15, a P/E/G ratio of 1.50 and a beta of 0.38. The company’s fifty day moving average price is $891.54 and its 200 day moving average price is $822.52.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. McKesson’s dividend payout ratio is 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.